SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin growth accelerates

Q3 FY2026 selling, general & admin of $4.28M rose 49.3% year over year, ahead of the +45.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.

Context

  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $123.37M (+907.0%) for the fiscal year ending Dec 2026, a step up from the -1.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$4.28M-1.8% QoQ
Last fiscal yearDec 2025
$12.25M-1.3% YoY
LTMSep 2026
$16.29M+45.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.3%+3399.9%+3350.6 pp
1 year-1.3%+907.0%+908.3 pp
3-year CAGR-0.9%+224.0%+224.9 pp
5-year CAGR+181.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
12.25M USD
Year-over-year change
-1.3%
4-year CAGR
+2.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +45.3% is the 6th highest of 11, against a peer median of +44.4%.
  • Over three fiscal years its annual growth of -0.9% compares with a peer median of +11.4%.
SLS Competitors
Selling, General & Admin for SLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.4B USD+8.2%+11.2%24.0%
AAPGAscentage Pharma Group InternationalFY2025CN¥522.67M CNY+36.4%+16.8%93.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M USD+57.0%+11.6%11.1%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$69.19M USD+65.4%+42.7%30.7%
IMNMImmunome, Inc.LTM Sep 2026$64.15M USD+52.3%+47.5%—
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.4M USD-16.4%-5.4%98.7%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$29.66M USD+100.0%+10.0%249.6%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$27.19M USD+59.1%+55.2%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$21.38M USD-22.5%-9.9%127.9%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$16.29M USD+45.3%-0.9%—
Peer median (excluding SLS) —+44.4%+11.4%62.2%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.6M1M000
Cost of Revenue200K100K000
Gross Profit7.4M900K000
Gross Margin97.4%90.0%———
Research & Development21.37M30.27M24.01M19.1M16.02M
Selling, General & Admin11.32M12.58M13.86M12.42M12.25M
Operating Expenses32.69M42.85M37.87M31.51M28.27M
Depreciation & Amortization1.27M457K37.87M31.51M0
EBITDA(18.32M)(31.49M)529K632K(26.86M)
EBITDA Margin-241.1%-3149.3%———
Operating Income(25.29M)(41.95M)(37.87M)(31.51M)(28.27M)
Operating Margin-332.8%-4195.0%———
Interest Income6K317K525K632K1.41M
Interest Expense00000
Other Income / Expenses4.36M649K529K632K1.41M
Income Before Tax(20.94M)(41.3M)(37.34M)(30.88M)(26.86M)
Pre-Tax Margin-275.5%-4130.1%———
Income Tax Expense(237K)0000
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Net Margin-272.4%-4130.1%———
EPS (Basic)(1.34)(2.13)(1.34)(0.50)(0.25)
EPS (Diluted)(1.34)(2.13)(1.34)(0.50)(0.25)
Weighted Avg Shares15.48M19.4M27.78M61.2M109.05M
Weighted Avg Shares (Diluted)15.48M19.4M27.78M61.2M109.05M

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.